Edwards Lifesciences Corporation

EW Healthcare Medical Devices

Edwards Lifesciences Corporation’s revenue for fiscal 2025 (year ended December 2025) was $6.1 billion, up 11.5% from fiscal 2024.

Revenue
+10.5%
EPS
+4.60%
Free cash flow
−1.84%
Total debt
+0.10%

Quarter to September 2026, against a year earlier

101.94 1.12 +1.11%
Market cap
$58.1B
P/E
57.8×
Fwd P/E
36.5×
Dividend yield
—
F-score
5/9
Altman Z
11.54
Beneish M
−2.48
Dividend safety
n/a
Sep '26 Jun '26 Mar '26 Dec '25 Older periods
ROE
9.65% 9.42% 10.68% 10.52%

+8 more TTM periods

Piotroski F-Score
7 5 5 5
ROA
7.45% 7.35% 8.32% 8.03%
ROIC
13.02% 12.81% 11.60% 11.78%
Return on Tangible Assets
13.56% 14.05% 16.50% 15.93%
Average Days of Receivables
51.28 53.56 56.34 54.87
Free Cash Flow per Share
2.47 2.49 1.88 2.28
Free Cash Flow
1,424.10 1,433.60 1,089.50 1,335.00
Other line items

Show all line items

Columns are period end dates · fundamentals updated 6 Nov 2026